Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.02 CAD
Change Today +0.23 / 12.85%
Volume 127.6K
RVX On Other Exchanges
As of 2:36 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

resverlogix corp (RVX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - C$3.14
52 Week Low
12/11/14 - C$0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESVERLOGIX CORP (RVX)

Related News

No related news articles were found.

resverlogix corp (RVX) Related Businessweek News

No Related Businessweek News Found

resverlogix corp (RVX) Details

Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing RVX-208, a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease. Resverlogix Corp. is headquartered in Calgary, Canada.

resverlogix corp (RVX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$404.6K
Chief Financial Officer
Total Annual Compensation: C$255.3K
Senior Vice President of Medical Affairs
Total Annual Compensation: C$276.0K
Senior Vice President of Clinical Development
Total Annual Compensation: C$214.3K
Senior Vice President of Business & Corporate...
Total Annual Compensation: C$238.7K
Compensation as of Fiscal Year 2015.

resverlogix corp (RVX) Key Developments

Resverlogix Closes License Agreement with Hepalink

Resverlogix Corp. announced that it has closed a license agreement with Shenzhen Hepalink Pharmaceutical Co. Ltd. Under the license between Resverlogix and Hepalink, should RVX-208 reach certain annual sales milestones in China, Hong Kong, Taiwan and Macau ranging from RMB 500 million to RMB 10 billion, Resverlogix will be eligible to receive sales-based milestone payments from Hepalink, each ranging from $5 million to $90 million. In addition, Hepalink will pay Resverlogix a royalty in the amount of 6% of net sales of RVX-208 in the Territories, subject to certain adjustments. The license will expire on a region-by-region basis on the later of the 15th anniversary of the first commercial sale in such region or the expiry date of the last-to-expire of any licensed patent. Hepalink will be responsible for all clinical and development costs in the Territories, including a patient population that will be included in Resverlogix's planned Phase 3 BETonMACE trial.

Resverlogix Corp. Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM

Resverlogix Corp. Presents at BIO International Convention 2015, Jun-17-2015 10:15 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Donald J. McCaffrey, Co-Founder, Chief Executive Officer, President, Secretary and Director.

Resverlogix Corp., Special/Extraordinary Shareholders Meeting, Jun 30, 2015

Resverlogix Corp., Special/Extraordinary Shareholders Meeting, Jun 30, 2015., at 09:00 Mountain Daylight. Location: The Telus Convention Centre, The Glen Room 206. Agenda: To consider and approve the amendment to the corporation's articles to change the rights, privileges, restrictions and conditions in respect of the Royalty Preferred Shares; to consider and approve a private placement to Eastern Capital Limited of 5,600,000 units of the corporation at a price of $2.67 per unit each unit being comprised one common share and 0.075358 common share purchase warrants and each whole warrant being exercisable at a price of $2.67 per share for a period of five years; and to transact such other business that may properly come before the meeting or adjournments thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVX:CN C$2.02 CAD +0.23

RVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESVERLOGIX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at